Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

Market Cap	23.51B
Revenue (ttm)	6.68B
Net Income (ttm)	2.22B
Shares Out	770.09M
EPS (ttm)	2.88
PE Ratio	12.13
Forward PE	32.38
Dividend	1.28 (3.66%)
Ex-Dividend Date	Jul 4, 2025

Volume	4,443,418
Average Volume	4,794,390
Open	35.01
Previous Close	34.97
Day's Range	34.89 - 35.40
52-Week Range	26.16 - 39.05
Beta	0.86
RSI	67.26
Earnings Date	Aug 15, 2025

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600329

Financial Performance

In 2024, SHA:600329's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.